Literature DB >> 30804125

Mid- to Long-term Outcomes After Split-thickness Skin Graft vs. Skin Extension by Multiple Incisions.

Jette Nicoline Kern1,2, Friederike Weidemann2, Padhraig F O'Loughlin3, Christian Krettek2, Ralph Gaulke4,2.   

Abstract

BACKGROUND/AIM: Skin extension by multiple incisions (SEMI) may be superior to split-thickness skin graft (STSG) for closure of large soft tissue defects.
MATERIALS AND METHODS: Twenty-six patients who had undergone STSG were compared to 29 patients who had undergone SEMI on the extremities. Patient and Observer Scar Assessment Scale (POSAS), Dermatology Life Quality Index, Wound QoL (Quality of Life) and Short Form Health Survey 36 were used. Elasticity, thickness and skin sensation were compared between the treated and contralateral extremity. Range of motion in adjacent joints was measured. Complication rates were compared.
RESULTS: A total of 55 patients with a mean follow-up of 5.5 years (range=2-9 years) were examined. Patients with STSG had significantly worse scores in POSAS. The scar was thinner, less elastic and did not provide intact sensibility. Other scores, ROM and complication rates did not differ significantly.
CONCLUSION: SEMI was superior to STSG regarding patient satisfaction and scar quality. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  SEMI; Split-thickness skin graft; skin extension by multiple incisions; skin quality; skin transplantation

Mesh:

Year:  2019        PMID: 30804125      PMCID: PMC6506296          DOI: 10.21873/invivo.11494

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  1 in total

1.  A retrospective study to evaluate the efficacy and safety of staged purse-string sutures for the reconstruction of surgical defects on skin using computer image analysis program.

Authors:  Gi Hyun Seong; Kyujin Yeom; Dea Kwan Yun; Mi Soo Choi; Myung Hwa Kim; Byung Cheol Park
Journal:  Indian J Dermatol       Date:  2021 Nov-Dec       Impact factor: 1.494

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.